Stock Events

Stock Events

GH Research 

$15.68
0
+$0+0% Wednesday 04:25

Statistics

Day High
15.72
Day Low
15.68
52W High
-
52W Low
-
Volume
1,185
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26FebExpected
Q3 2025
Next
-0.27
-0.25
-0.24
-0.23
Expected EPS
-0.266667
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GHRS.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap606.35M
Compass Pathways operates in the psychedelic medicine space, focusing on psilocybin therapy for depression, directly competing with GH Research's focus on mental health treatments.
Mind Medicine Inc
MNMD
Mkt Cap1.38B
Mind Medicine works on developing psychedelic-inspired therapies, including for mental health issues, which aligns with GH Research's therapeutic areas.
AtaiBeckley
ATAI
Mkt Cap1.56B
ATAI Life Sciences is a biotech company with a focus on psychedelic and non-psychedelic compounds for mental health disorders, competing in the same space as GH Research.
Cybin Inc
CYBN
Mkt Cap200.49M
Cybin Inc. is developing psychedelic compounds for various mental health conditions, making it a direct competitor to GH Research in the psychedelic treatment market.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness focuses on psychedelic production and therapy, including mental health treatments, positioning it as a competitor to GH Research.
Revive Therapeutics
RVVTF
Mkt Cap4.68M
Revive Therapeutics explores the use of psychedelics in treatments, including mental health, which competes with GH Research's therapeutic focus.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its subsidiary Janssen Pharmaceuticals, has developed a ketamine-based treatment for depression, competing in the mental health treatment space with GH Research.

About

GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Show more...
CEO
Mr. Florian Schonharting M.Sc. (Econ)
Employees
50
Country
IE
ISIN
IE000GID8VI0

Listings

F
DE
1KA.F
XNAS
US
GHRS
BOATS
BOATS
GHRS.BOATS

0 Comments

Share your thoughts

FAQ

What is GH Research stock price today?▼
The current price of GHRS.BOATS is $15.68 USD — it has increased by +0% in the past 24 hours. Watch GH Research stock price performance more closely on the chart.
What is GH Research stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange GH Research stocks are traded under the ticker GHRS.BOATS.
When is the next GH Research earnings date?▼
GH Research is going to release the next earnings report on February 26, 2026.
What were GH Research earnings last quarter?▼
GHRS.BOATS earnings for the last quarter are -0.23 USD per share, whereas the estimation was -0.24 USD resulting in a +2.82% surprise. The estimated earnings for the next quarter are N/A USD per share.
How many employees does GH Research have?▼
As of February 03, 2026, the company has 50 employees.
In which sector is GH Research located?▼
GH Research operates in the Health Care sector.
When did GH Research complete a stock split?▼
GH Research has not had any recent stock splits.
Where is GH Research headquartered?▼
GH Research is headquartered in Dublin, IE.